A change in the fair value of investments held by Imperial Innovations, the hot-house for technology and healthcare ideas from Britain's universities, saw full year profits surge.
Revenues eased, however, reflecting the continuing difficult economic environment. Total revenues in the year to the end of July fell to £4.3m from £4.5m the year before, but were ahead of the market consensus forecast of £4.05m.
Licence and royalty revenue from initial licence payments and intellectual property licences was £1.6m, down from £1.9m the previous year.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Start your trial
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Revenue from services, which includes intellectual property management consultancy fees, rose to £1.4m from £1.2m.
Latest Videos FromMoneyWeek
Corporate finance fees of £1.2m, down from the previous year's £1.3m, were primarily generated by the group-led funding rounds.
Dividends received were a bit skimpy, at £44,000, compared to divis of £0.2m the previous year.
Profit before tax leapt to £5.08m from £0.58m the previous year, as the value of the group's investments was marked up by a net £14.69m, versus a gain the prior year of £3.26m.
Fair value gains of £21.6m were offset by offset by general impairments of £6.9m and a £2.3m impairment specific to life sciences firm Thiakis, where milestone payments are looking less likely after US pharmaceuticals Pfizer announced in April 2012 it was discontinuing research & development investment in the firm's products.
At July 31st the group held equity stakes in 82 companies, up from 78 a year earlier. The value of the portfolio increased to £155.6m from £104.5m year-on-year, while the value of net assets rose to £228.2m from £224.1m.
During the course of the year the group invested a record £37.9m in 29 companies, up from £35.1m the year before, when the company ploughed money into 23 companies.
"This is consistent with our view that early stage technology companies need to be funded properly to attract strong management and build businesses of scale and significance. It is worth noting that some £94.2m has been invested by us in our top 15 investee companies. Some of these are significant businesses in their own right, far removed from the 'spin-out' tag," claimed Martin Knight, Chairman of Imperial Innovations.
Companies in the portfolio raised a total £147m in cash and investment commitments, up from £129m the year before.
"We are committed to building substantial businesses based on intellectual property emanating from the UK's leading research intensive universities. We are not investors distracted from this goal by one eye permanently on the door marked 'exit'," avowed Knight.
"We remain confident that our progress will be maintained, with continuing value being built in our portfolio of companies," Knight added.
JH
